MX2022010280A - Metodos y composiciones para modular las concentraciones de arginina en celulas inmunitarias. - Google Patents

Metodos y composiciones para modular las concentraciones de arginina en celulas inmunitarias.

Info

Publication number
MX2022010280A
MX2022010280A MX2022010280A MX2022010280A MX2022010280A MX 2022010280 A MX2022010280 A MX 2022010280A MX 2022010280 A MX2022010280 A MX 2022010280A MX 2022010280 A MX2022010280 A MX 2022010280A MX 2022010280 A MX2022010280 A MX 2022010280A
Authority
MX
Mexico
Prior art keywords
arginine
cells
methods
compositions
modulating
Prior art date
Application number
MX2022010280A
Other languages
English (en)
Inventor
Kwok Ming Cheung
Original Assignee
Sky Perfect International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sky Perfect International Ltd filed Critical Sky Perfect International Ltd
Publication of MX2022010280A publication Critical patent/MX2022010280A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4637—Other peptides or polypeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

En el presente documento se divulgan células T y células T-CAR modificadas genéticamente y que tienen una capacidad aumentada para procesar el aminoácido esencial arginina, por ejemplo, mediante la sobreexpresión de transportadores de aminoácidos, particularmente, transportadores de arginina. Dichas células T y células T-CAR modificadas genéticamente pueden mejorar su supervivencia en el microentorno tumoral, generalmente hostil, gracias a su capacidad aumentada para procesar arginina. Los métodos y composiciones descritos en el presente documento se usan para aumentar la cantidad de arginina a disposición de una célula T. Los métodos y composiciones descritos en el presente documento también se usan para aumentar la cantidad de arginina a disposición de una célula T-CAR, proporcionando de esta manera una célula T-CAR que puede ser eficaz en el tratamiento contra tumores sólidos, al sobrevivir en el microentorno tumoral.
MX2022010280A 2020-02-21 2021-02-20 Metodos y composiciones para modular las concentraciones de arginina en celulas inmunitarias. MX2022010280A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062979805P 2020-02-21 2020-02-21
PCT/CN2021/077002 WO2021164753A1 (en) 2020-02-21 2021-02-20 Methods and compositions for modulating arginine levels in immune cells

Publications (1)

Publication Number Publication Date
MX2022010280A true MX2022010280A (es) 2022-11-16

Family

ID=77390457

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010280A MX2022010280A (es) 2020-02-21 2021-02-20 Metodos y composiciones para modular las concentraciones de arginina en celulas inmunitarias.

Country Status (13)

Country Link
US (1) US20230265386A1 (es)
EP (1) EP4107254A1 (es)
JP (1) JP2023515806A (es)
KR (1) KR20220157396A (es)
CN (1) CN115427553A (es)
AR (1) AR121392A1 (es)
AU (1) AU2021223138A1 (es)
BR (1) BR112022016571A2 (es)
CA (1) CA3171901A1 (es)
IL (1) IL295606A (es)
MX (1) MX2022010280A (es)
TW (1) TW202144569A (es)
WO (1) WO2021164753A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202018554D0 (en) * 2020-11-25 2021-01-06 Cancer Research Tech Ltd Nucleic acid constructs and cells
CN114788870B (zh) * 2022-04-29 2023-06-06 浙江大学 靶向免疫细胞长效补充精氨酸并中和酸环境的组合物及应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201701332D0 (en) * 2017-01-26 2017-03-15 Tc Biopharm Ltd Immune cells with modified metabolism and their use thereof

Also Published As

Publication number Publication date
WO2021164753A1 (en) 2021-08-26
AU2021223138A1 (en) 2022-09-29
EP4107254A1 (en) 2022-12-28
CN115427553A (zh) 2022-12-02
BR112022016571A2 (pt) 2022-11-16
IL295606A (en) 2022-10-01
KR20220157396A (ko) 2022-11-29
JP2023515806A (ja) 2023-04-14
US20230265386A1 (en) 2023-08-24
TW202144569A (zh) 2021-12-01
CA3171901A1 (en) 2021-08-26
AR121392A1 (es) 2022-06-01

Similar Documents

Publication Publication Date Title
MX2022010280A (es) Metodos y composiciones para modular las concentraciones de arginina en celulas inmunitarias.
MX2021000165A (es) Cepas bacterianas inmunoestimuladoras modificadas y usos de las mismas.
MX2019000149A (es) Proteinas de union a ligando 1 de muerte programada 1 (pd-l1) y metodos de uso de las mismas.
EP4219690A3 (en) Methods of cancer treatment using activated t cells
MX2022015586A (es) Linfocitos citolíticos naturales modificados genéticamente para inmunoterapia de cáncer dirigida a cd70.
MX2020011675A (es) Peptidos novedosos y acidos nucleicos de los mismos contra tumores tal como los de cancer gastrico y gastrointestinal.
MX2022005815A (es) Terapia para neoplasias malignas de celulas hematopoyeticas utilizando linfocitos t modificados geneticamente que se dirigen a cd70.
MX2021009357A (es) Dianas de genes de combinacion para mejorar la inmunoterapia.
MX2022001977A (es) Poblaciones de celulas t gamma delta t ex vivo.
WO2020107002A3 (en) Methods for expansion of natural killer (nk) cell subset and related compositions and methods
MX2022005821A (es) Terapia del carcinoma de celulas renales (rcc) usando linfocitos t modificados por ingenieria genetica dirigidos a cd70.
MX2022005816A (es) Terapia de tumores solidos cd70+ utilizando linfocitos t genomodificados dirigidos a cd70.
MX2021013368A (es) Celulas t del receptor de antigenos quimericos focalizadas a cd19 especificas del antigeno.
MX2021005372A (es) Composiciones de linfocitos t con propiedades fenotípicas mejoradas.
MX2022007833A (es) Nuevos receptores de antigenos quimericos (car) especificos de mesotelina para inmunoterapia de cancer de tumores solidos.
MX2022004772A (es) Composiciones y métodos para la activación y la expansión in vitro de poblaciones de linfocitos t citolíticos en serie e inmunización pasiva de un paciente de cáncer con células tumorales asesinas.
WO2022164976A3 (en) Immunostimulatory cytokine combination and therapeutic use thereof
MX2022012990A (es) Proceso para generar células t autólogas modificadas genéticamente.
MX2022007779A (es) Tratamiento que involucra celulas efectoras inmunitarias modificadas geneticamente para expresar receptores de antigenos.
MX2021012236A (es) Metodo para mejorar la inmunoterapia celular.
ZA202306735B (en) Methods of selectively targeting cd6 high cells and decreasing activity of t eff cells
AU2019356414A8 (en) Binding proteins specific for HA-1H and uses thereof
MX2023006869A (es) Proteinas de union condicionalmente biespecificas.
WO2022256546A3 (en) Gene editing in primary immune cells using cell penetrating crispr-cas system
MX2021010998A (es) Metodos para mejorar la eficacia en el agotamiento de celulas tcr a?+.